Disruption of the Bcr-Abl/Jak2/HSP90 complex by ON044580, a dual kinase inhibitor against Jak2 and c-Abl, resulted in Bcr-Abl protein degradation and apoptosis of CML cells. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.